14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
MRNA vs ADPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). MRNA carries a Unified Composite Score of 46.6/100 (HOLD) at $206.00 (23.0x Forward P/E, -80.8% operating margin), whereas ADPT carries 43.2/100 (HOLD) at $28.46 (N/M Forward P/E, -16.2% operating margin).
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment62.4% of Rev ($186M)
90D Engineering Disclosures0 Published
Investor FAQ MRNA vs ADPT Key Questions & Quantitative Answers
As of Nov 17, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). MRNA carries a Unified Composite Score of 46.6/100 (HOLD) at $206.00 (23.0x Forward P/E, -80.8% operating margin), whereas ADPT carries 43.2/100 (HOLD) at $28.46 (N/M Forward P/E, -16.2% operating margin). Technically, MRNA sits in a Neutral phase (RSI 44.4, CONSOLIDATION options structure) and ADPT sits in a Markup phase (RSI 54.6, BREAKOUT options structure).
MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.
MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 37.0x EV/Revenue (-81.0% FCF margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus ADPT (-36.4% ROE) capital efficiency.
In options market volatility and institutional positioning, MRNA carries 100.2% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 1.29x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.37β · 100% Vol realized risk). By comparison, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.